Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

InMed Pharmaceuticals Inc. (C:IN)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: SUITE 310, 815 W. HASTINGS STREET
Tel: N/A
IR: See website
Key People
William J. Garner
Chairman of the Board
Eric A. Adams
President, Chief Executive Officer, Director
Bruce S. Colwill
Chief Financial Officer
Alexandra D.J. Mancini
Senior Vice President - Clinical and Regulatory Affairs
Josh Blacher
Chief Business Officer
Abo Mohammed
Chief Medical Officer
Business Overview
InMed Pharmaceuticals Inc. is a pre-clinical-stage biopharmaceutical company. The Company specializes in the research and development of cannabinoid-based therapies combined with drug delivery systems. The Company operates through the segment of research and development of pharmaceutical cannabis based-therapies. The Company is working on two products, which include INM-750, for the treatment of Epidermolysis Bullosa (EB), and INM-085, for the treatment of Glaucoma. The INM-750 is a therapy developed for EB designed specifically to modulate disease activity and to alleviate symptoms. The INM-085 is designed as a dual-action cannabinoid ocular therapy. INM-085 is designed as a topical formulation to be administered directly to the eye. It is working on the development of several cannabinoid-based treatments for multiple diseases, including ocular, dermatology, cancer, inflammation, pain and arthritis disease areas. Its subsidiary is Biogen Sciences Inc. (BSI).
Financial Overview
For the nine months ended 31 March 2020, InMed Pharmaceuticals Inc revenues was not reported. Net loss increased 6% to C$9.5M. Higher net loss reflects Accounting and legal increase of 68% to C$683K (expense), Other Income (Loss) Interest income decrease of 51% to C$166K (income), Salaries and benefits increase of 15% to C$1.3M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -C$1.73 to -C$1.83.
Employees: 12 as of Jun 30, 2019
Reporting Currency: Canadian Dollars
Enterprise value: $29.94M as of Mar 31, 2020
Annual revenue (TTM): $0.00M as of Mar 31, 2020
EBITDA (TTM): -$14.01M as of Mar 31, 2020
Net annual income (TTM): -$13.81M as of Mar 31, 2020
Free cash flow (TTM): -$10.35M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 5,220,716 as of Jul 3, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization